370
Participants
Start Date
November 24, 2023
Primary Completion Date
November 30, 2024
Study Completion Date
November 30, 2024
Iohexol (320mgI/mL) with 120kVp
Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Iohexol (320mgI/mL) with 100kVp
Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Iohexol (270mgI/mL) with 100kVp
Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Iohexol (240mgI/mL) with 100kVp
Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
COMPLETED
Bucheon St. Mary's Hospital, The Catholic University of Korea, Bucheon-si
RECRUITING
Pusan National University Yangsan Hospital, Yangsan
RECRUITING
Jeonbuk National University Hospital, Jeonju
COMPLETED
Chonnam National University Hospital, Gwangju
RECRUITING
Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul
COMPLETED
Seoul National University Hospital, Seoul
Taejoon Pharmaceutical Co., Ltd.
INDUSTRY
Jung Im Jung
OTHER